Search research articles
Contact Us
Filters
Showing results (61-70 of 301) with videos related to
Page
of 31
Sort By:
Frontiers in Oncology
|
January 29, 2019
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
Katarina K Jovanović, Guillaume Escure, Jordane Demonchy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
The Lancet. Oncology
|
October 12, 2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Michel Delforge, Joan Bladé, Meletios A Dimopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 3, 2012
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients
Olivier Decaux, Alain Renault, Véronique Sébille, et al.
BMC Pharmacology & Toxicology
|
August 14, 2013
Memory loss during lenalidomide treatment: a report on two cases
Adeline Rollin-Sillaire, Xavier Delbeuck, Marianne Pollet, et al.
Leukemia & Lymphoma
|
February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
Julie M Vose, Amit Panwalkar, Robert Belanger, et al.
Blood
|
February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
Blood
|
August 19, 2011
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study
Selim Corm, Laurent Roche, Jean-Baptiste Micol, et al.
Ejhaem
|
July 18, 2022
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
Pieter Sonneveld, María-Victoria Mateos, Adrian Alegre, et al.
JAMA Oncology
|
September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis
Smith Giri, Alyssa Grimshaw, Susan Bal, et al.
Page
of 31
Search research articles
Search
Showing results (61-70 of 301) with videos related to
Sort By:
Page
of 31
Frontiers in Oncology
|
January 29, 2019
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
Katarina K Jovanović, Guillaume Escure, Jordane Demonchy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
David S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
The Lancet. Oncology
|
October 12, 2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Michel Delforge, Joan Bladé, Meletios A Dimopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 3, 2012
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients
Olivier Decaux, Alain Renault, Véronique Sébille, et al.
BMC Pharmacology & Toxicology
|
August 14, 2013
Memory loss during lenalidomide treatment: a report on two cases
Adeline Rollin-Sillaire, Xavier Delbeuck, Marianne Pollet, et al.
Leukemia & Lymphoma
|
February 28, 2007
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
Julie M Vose, Amit Panwalkar, Robert Belanger, et al.
Blood
|
February 5, 2008
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo, Thierry Facon, Pieter Sonneveld, et al.
Blood
|
August 19, 2011
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study
Selim Corm, Laurent Roche, Jean-Baptiste Micol, et al.
Ejhaem
|
July 18, 2022
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
Pieter Sonneveld, María-Victoria Mateos, Adrian Alegre, et al.
JAMA Oncology
|
September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis
Smith Giri, Alyssa Grimshaw, Susan Bal, et al.
Page
of 31